The life science company Sartorius provided an outlook for the current fiscal year and reported double-digit sales revenue and earnings growth for the first nine months of 2022 in both divisions.

“In a difficult environment, Sartorius made tremendous progress in the first nine months. Despite negative trends in costs and currency, both divisions saw double-digit growth in sales revenue and very strong profit margins. The lab division expanded quite quickly, with the bioanalytics sector performing particularly well. The surge of sales revenue in the bioprocessing industry was notable, and as was to be predicted, the demand quickly returned to normal after two years of being strongly influenced by the pandemic’s particular impacts.

With the acquisition of Albumedix, we increased the division’s portfolio and added a crucial component for the production of novel biopharmaceuticals, particularly in the context of modalities like cell treatments, viral therapies, and vaccines. Executive Board Chairman and CEO Joachim Kreuzburg stated, “We are defining our full-year outlook for 2022 within the range anticipated thus far, but the global political and economic uncertainties remain high.

Source: Prnewswire